# US 2019/0169300 A1 · Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169300 A1
- Document ID: US20190169300A1
- Status: Published application
- Kind: A1
- Application number: 16/322,964
- Filed: 2017-08-03
- Published: 2019-06-06
- Earliest claimed: 2016-08-03
- Assignees: REMD Biotherapeutics, Inc.
- Applicants: REMD Biotherapeutics, Inc.
- Inventors: Frank J Calzone
- Web page: https://patentgrep.com/patent/US20190169300A1

## CPC

- C07K 16/2869: {against hormone receptors (for antibodies against neuromediator receptors C07K16/286)}
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- A61K 2039/541: {Mucosal route}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to combination therapy methods of treating a subject having cancer, comprising administering to the subject a) an effective amount of a pharmaceutical composition comprising a phosphatidylinositol 3-kinase (PI3K) pathway inhibitor, or a pharmaceutically acceptable salt thereof, and b) an effective amount of a pharmaceutical composition comprising a glucagon receptor antagonist.

## Claims

### Claim at position 1

1-33. (canceled)

### Claim 34

A method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a phosphatidylinositol 3-kinase (PI3K) pathway inhibitor, and a therapeutically effective amount of an isolated glucagon receptor (GCGR) antagonist.

### Claim 35 (depends on 34)

A method according to claim 34, wherein the isolated GCGR antagonist comprises an isolated GCGR antagonistic antibody or antigen-binding fragment selected from the group consisting of a fully human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a Fab, a Fab′, a Fab2, a Fab′2, a IgG, a IgM, a IgA, a IgE, a scFv, a dsFv, a dAb, a nanobody, a unibody, a diabody, and a hemibody, wherein the isolated GCGR antagonistic antibody or antigen-binding antibody fragment specifically binds to a human glucagon receptor with a dissociation constant (KD) of at least about 1×10−7 M, at least about 1×10−8 M, at least about 1×10−8 M, at least about 1×10−10M, at least about 1×10−11 M, or at least about 1×10−12 M.

### Claim 36 (depends on 35)

A method according to claim 35, wherein the isolated GCGR antagonistic antibody is a fully human antibody.

### Claim 37 (depends on 36)

A method according to claim 36, wherein the fully human antibody comprises a human anti-GCGR antibody which comprises the amino acid sequence encoding the heavy chain of SEQ ID NO: 49 and the amino acid sequence encoding the light chain of SEQ ID NO: 50.

### Claim 38 (depends on 35)

A method according to claim 35, wherein the therapeutically effective amount of the isolated GCGR antagonist antibody or antigen-binding fragment is selected from the group consisting of: 0.001 to 10 mg/kg, 0.001 to 9 mg/kg, 0.001 to 8 mg/kg, 0.001 to 7 mg/kg, 0.001 to 6 mg/kg, 0.001 to 5 mg/kg, 0.001 to 4 mg/kg, 0.001 to 3 mg/kg, 0.001 to 20 mg/kg, 0.001 to 1 mg/kg, 0.010 to 10 mg/kg, 0.010 to 9 mg/kg, 0.010 to 8 mg/kg, 0.010 to 7 mg/kg, 0.010 to 6 mg/kg, 0.010 to 5 mg/kg, 0.010 to 4 mg/kg, 0.010 to 3 mg/kg, 0.010 to 2 mg/kg, 0.010 to 1 mg/kg, 0.1 to 10 mg/kg, 0.1 to 9 mg/kg, 0.1 to 8 mg/kg, 0.1 to 7 mg/kg, 0.1 to 6 mg/kg, 0.1 to 5 mg/kg, 0.1 to 4 mg/kg, 0.1 to 3 mg/kg, 0.1 to 2 mg/kg, 0.1 to 1 mg/kg, 0.5 to 10 mg/kg, 0.5 to 9 mg/kg, 0.5 to 8 mg/kg, 0.5 to 7 mg/kg, 0.5 to 6 mg/kg, 0.5 to 5 mg/kg, 0.5 to 4 mg/kg, 0.5 to 3 mg/kg, 0.5 to 2 mg/kg, 0.5 to 1 mg/kg, 1 to 10 mg/kg, 1 to 9 mg/kg, 1 to 8 mg/kg, 1 to 7 mg/kg, 1 to 6 mg/kg, 1 to 5 mg/kg, 1 to 4 mg/kg, 1 to 3 mg/kg, and 1 to 2 mg/kg body weight per week.

### Claim 39 (depends on 34)

A method according to claim 34, wherein the PI3K pathway inhibitor is a PI3K inhibitor selected from the group consisting of an PI3K alpha inhibitor, an PI3K beta inhibitor, an PI3K gamma inhibitor, an PI3K delta inhibitor, and an pan-PI3K isoform inhibitor.

### Claim 40 (depends on 39)

A method according to claim 39, wherein the PI3K inhibitor is selected from the group consisting of: selected from the group consisting of: GDC-0941, BKM120 (NVP-BKM120), XL147, PX-866, BAY806946, CH5132799, BYL719 (NVP-BYL719), MLN1117, AZD8186, SAR260301, GSK2636771, GS-1101, AMG 319, GS-9820, IPI-145, GDC-0032, and GDC-0084.

### Claim 41 (depends on 34)

A method according to claim 34, wherein the PI3K pathway inhibitor is selected from the group consisting of an insulin-like growth factor receptor 1 (IGFR1) small molecule tyrosine kinase inhibitor, and an IGFR1 monoclonal antibody.

### Claim 42 (depends on 41)

A method according to claim 41, wherein the IGFR1 small molecule tyrosine kinase inhibitor is selected from the group consisting of: BMS 754807, INSM-18, OSI-906 (linsitinib), XL-228, GSK 1904529A, ABDP, A-928605, AXL1717 (PPP), KW-2450, NVP-ADW742, NVP-AEW541, AG-1024, BMS-536924, BMS-554417, and BVP-51004.

### Claim 43 (depends on 41)

A method according to claim 41, wherein the IGFR1 monoclonal antibody is selected from the group consisting of: MK 0646 (dalotuzumab), AMG 479 (ganitumumab), A12 (cixutumumab), CP 751,871 (figitumumab), AVE1642, Sch717454 (robatumumab), R 1507, BIIB022, h10H5, MEDI-573, and BI836845.

### Claim 44 (depends on 34)

A method according to claim 34, wherein the PI3K pathway inhibitor is an AKT inhibitor.

### Claim 45 (depends on 44)

A method according to claim 44, wherein the AKT inhibitor is selected from the group consisting of: miltefosine, perifosine, PF-04691502, CCT128930, A-674563, MK-2206, RX-0201, PBI-05204, AZD5363, GDC-0068 (Ipatasertib), TIC10, Akti-1/2, AT7867, AT13148, SC79, GSK690693, GSK2110183 and GSK2141795.

### Claim 46 (depends on 34)

A method according to claim 34, wherein the PI3K pathway inhibitor is selected from the group consisting of a mTOR inhibitor and a pan PI3K/mTOR inhibitor.

### Claim 47 (depends on 46)

A method according to claim 46, wherein the mTOR inhibitor is selected from the group consisting of: sirolimus, RAD001 (everolimus), CCI-779 (temsirolimus), ABT578, SAR543, ascomycin, ridaforolimus, AP23573 (deforolimus), AP23841, KU-0063794, INK-128, EX2044, EX3855, EX7518, MK-8669, AZD08055, MLN0128, AZD2014, CC-223 and OSI027, and wherein the pan PI3K/mTOR inhibitor is selected from the group consisting of: NVP-BEZ235, NVP-BGT226, XL765, GSK1059615, and GDC-0980.

### Claim 48 (depends on 34)

A method according to claim 34, wherein the therapeutically effective amount of the PI3K pathway inhibitor is selected from the group consisting of 0.05 mg/kg to 75 mg/kg, 0.05 mg/kg to 70 mg/kg, 0.05 mg/kg to 60 mg/kg, 0.05 mg/kg to 50 mg/kg, 0.05 mg/kg to 40 mg/kg, 0.05 mg/kg to 30 mg/kg, 0.05 mg/kg to 20 mg/kg, 0.05 mg/kg to 10 mg/kg, 0.1 mg/kg to 75 mg/kg, 0.1 mg/kg to 30 mg/kg, 0.1 mg/kg to 40 mg/kg, 0.1 mg/kg to 50 mg/kg, 0.1 mg/kg to 40 mg/kg, 0.1 mg/kg to 30 mg/kg, 0.1 mg/kg to 20 mg/kg, 0.1 mg/kg to 10 mg/kg, 0.5 mg/kg to 75 mg/kg, 0.5 mg/kg to 70 mg/kg, 0.5 mg/kg to 60 mg/kg, 0.5 mg/kg to 50 mg/kg, 0.5 mg/kg to 40 mg/kg, 0.5 mg/kg to 30 mg/kg, 0.5 mg/kg to 20 mg/kg, 0.5 mg/kg to 10 mg/kg, 1 mg/kg to 75 mg/kg, 1 mg/kg to 70 mg/kg, 1 mg/kg to 60 mg/kg, 1 mg/kg to 50 mg/kg, 1 mg/kg to 40 mg/kg, 1 mg/kg to 30 mg/kg, 1 mg/kg to 20 mg/kg, 1 mg/kg to 10 mg/kg, 5 mg/kg to 75 mg/kg, 5 mg/kg to 70 mg/kg, 5 mg/kg to 60 mg/kg, 5 mg/kg to 50 mg/kg, 5 mg/kg to 40 mg/kg, 5 mg/kg to 30 mg/kg, 5 mg/kg to 20 mg/kg, and 5 mg/kg to 10 mg/kg body weight of the recipient per day.

### Claim 49 (depends on 34)

A method according to claim 34, wherein the PI3K pathway inhibitor and GCGR antagonist are administered at substantially the same time.

### Claim 50 (depends on 34)

A method according to claim 34, wherein the PI3K pathway inhibitor and GCGR antagonist are administered at different times.

### Claim 51 (depends on 34)

A method according to claim 34, wherein the cancer is selected from the group consisting of: B cell lymphoma; a lung cancer (small cell lung cancer and non-small cell lung cancer); a bronchus cancer; a colorectal cancer; a prostate cancer; a breast cancer; a pancreas cancer; a stomach cancer; an ovarian cancer; a urinary bladder cancer; a brain or central nervous system cancer; a peripheral nervous system cancer; an esophageal cancer; a cervical cancer; a melanoma; a uterine or endometrial cancer; a cancer of the oral cavity or pharynx; a liver cancer; a kidney cancer; a biliary tract cancer; a small bowel or appendix cancer; a salivary gland cancer; a thyroid gland cancer; a adrenal gland cancer; an osteosarcoma; a chondrosarcoma; a liposarcoma; a testes cancer; and a malignant fibrous histiocytoma; a skin cancer; a head and neck cancer; lymphomas; sarcomas; multiple myeloma; and leukemias.

### Claim 52 (depends on 51)

A method according to claim 51, wherein the cancer is a recurrent cancer.

### Claim 53 (depends on 51)

A method according to claim 51, wherein the cancer is resistant to or refractory to treatment with a PI3K pathway inhibitor.
